FULC – fulcrum therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 [Yahoo! Finance]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
Form 8-K Fulcrum Therapeutics, For: Feb 26
Form S-8 Fulcrum Therapeutics,
Form 10-K Fulcrum Therapeutics, For: Dec 31
Form 8-K Fulcrum Therapeutics, For: Feb 25
Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: Adage Capital Management, L.P.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.